Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents
Aims: In this pandemic, it is essential for rheumatologists and patients to know the relationship between COVID-19 and inflammatory rheumatic diseases (IRDs). We wanted to assess the role of targeted synthetic or biologic disease-modifying antirheumatic drugs (ts/bDMARDs) and other variables in the...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-02-01
|
Series: | Therapeutic Advances in Musculoskeletal Disease |
Online Access: | https://doi.org/10.1177/1759720X20962692 |
id |
doaj-2a7c01614dc8463d826e56763ed35c1d |
---|---|
record_format |
Article |
spelling |
doaj-2a7c01614dc8463d826e56763ed35c1d2021-07-14T12:03:59ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182021-02-011310.1177/1759720X20962692Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agentsBenjamin Fernandez-GutierrezLeticia LeonAlfredo MadridLuis Rodriguez-RodriguezDalifer FreitesJudit FontArkaitz MucientesEsther CulebrasJose Ignacio ColomeJuan Angel JoverLydia AbasoloAims: In this pandemic, it is essential for rheumatologists and patients to know the relationship between COVID-19 and inflammatory rheumatic diseases (IRDs). We wanted to assess the role of targeted synthetic or biologic disease-modifying antirheumatic drugs (ts/bDMARDs) and other variables in the development of moderate-severe COVID-19 disease in IRD. Methods: An observational longitudinal study was conducted during the epidemic peak in Madrid (1 March to 15 April 2020). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid with a medical diagnosis of IRD were included. Main outcome: hospital admission related to COVID-19. Independent variable: ts/bDMARDs. Covariates: sociodemographic, comorbidities, type of IRD diagnosis, glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Incidence rate (IR) of hospital admission related to COVID-19 was expressed per 1000 patient-months. Cox multiple regression analysis was run to examine the influence of ts/bDMARDs and other covariates on IR of hospital admission related to COVID-19. Results: A total of 3951 IRD patients were included (5896 patient-months). Methotrexate was the csDMARD most used. Eight hundred and two patients were on ts/bDMARDs, mainly anti-TNF agents, and Rtx. Hospital admissions related to COVID-19 occurred in 54 patients (1.36%) with an IR of 9.15 (95% confidence interval: 7–11.9). In the multivariate analysis, older, male, comorbidities, and specific systemic autoimmune conditions (Sjögren, polychondritis, Raynaud, and mixed connective tissue disease) had more risk of hospital admissions. Exposition to ts/bDMARDs did not achieve statistical significance. Use of glucocorticoids, NSAIDs, and csDMARDs dropped from the final model. Conclusion: This study provides additional evidence in IRD patients regarding susceptibility to moderate–severe infection related to COVID-19.https://doi.org/10.1177/1759720X20962692 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Benjamin Fernandez-Gutierrez Leticia Leon Alfredo Madrid Luis Rodriguez-Rodriguez Dalifer Freites Judit Font Arkaitz Mucientes Esther Culebras Jose Ignacio Colome Juan Angel Jover Lydia Abasolo |
spellingShingle |
Benjamin Fernandez-Gutierrez Leticia Leon Alfredo Madrid Luis Rodriguez-Rodriguez Dalifer Freites Judit Font Arkaitz Mucientes Esther Culebras Jose Ignacio Colome Juan Angel Jover Lydia Abasolo Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents Therapeutic Advances in Musculoskeletal Disease |
author_facet |
Benjamin Fernandez-Gutierrez Leticia Leon Alfredo Madrid Luis Rodriguez-Rodriguez Dalifer Freites Judit Font Arkaitz Mucientes Esther Culebras Jose Ignacio Colome Juan Angel Jover Lydia Abasolo |
author_sort |
Benjamin Fernandez-Gutierrez |
title |
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents |
title_short |
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents |
title_full |
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents |
title_fullStr |
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents |
title_full_unstemmed |
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents |
title_sort |
hospital admissions in inflammatory rheumatic diseases during the peak of covid-19 pandemic: incidence and role of disease-modifying agents |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Musculoskeletal Disease |
issn |
1759-7218 |
publishDate |
2021-02-01 |
description |
Aims: In this pandemic, it is essential for rheumatologists and patients to know the relationship between COVID-19 and inflammatory rheumatic diseases (IRDs). We wanted to assess the role of targeted synthetic or biologic disease-modifying antirheumatic drugs (ts/bDMARDs) and other variables in the development of moderate-severe COVID-19 disease in IRD. Methods: An observational longitudinal study was conducted during the epidemic peak in Madrid (1 March to 15 April 2020). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid with a medical diagnosis of IRD were included. Main outcome: hospital admission related to COVID-19. Independent variable: ts/bDMARDs. Covariates: sociodemographic, comorbidities, type of IRD diagnosis, glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Incidence rate (IR) of hospital admission related to COVID-19 was expressed per 1000 patient-months. Cox multiple regression analysis was run to examine the influence of ts/bDMARDs and other covariates on IR of hospital admission related to COVID-19. Results: A total of 3951 IRD patients were included (5896 patient-months). Methotrexate was the csDMARD most used. Eight hundred and two patients were on ts/bDMARDs, mainly anti-TNF agents, and Rtx. Hospital admissions related to COVID-19 occurred in 54 patients (1.36%) with an IR of 9.15 (95% confidence interval: 7–11.9). In the multivariate analysis, older, male, comorbidities, and specific systemic autoimmune conditions (Sjögren, polychondritis, Raynaud, and mixed connective tissue disease) had more risk of hospital admissions. Exposition to ts/bDMARDs did not achieve statistical significance. Use of glucocorticoids, NSAIDs, and csDMARDs dropped from the final model. Conclusion: This study provides additional evidence in IRD patients regarding susceptibility to moderate–severe infection related to COVID-19. |
url |
https://doi.org/10.1177/1759720X20962692 |
work_keys_str_mv |
AT benjaminfernandezgutierrez hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents AT leticialeon hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents AT alfredomadrid hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents AT luisrodriguezrodriguez hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents AT daliferfreites hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents AT juditfont hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents AT arkaitzmucientes hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents AT estherculebras hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents AT joseignaciocolome hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents AT juanangeljover hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents AT lydiaabasolo hospitaladmissionsininflammatoryrheumaticdiseasesduringthepeakofcovid19pandemicincidenceandroleofdiseasemodifyingagents |
_version_ |
1721302999334125568 |